| US 7,592,304 B2 | ||
| Metal-binding compounds and uses therefor | ||
| David Bar-Or, Englewood, Colo. (US) | ||
| Assigned to DMI Life Sciences, Inc., Greenwood Village, Colo. (US) | ||
| Filed on Feb. 13, 2002, as Appl. No. 10/76,071. | ||
| Application 10/076071 is a continuation in part of application No. 09/678202, filed on Sep. 29, 2000, abandoned. | ||
| Claims priority of provisional application 60/283507, filed on Apr. 11, 2001. | ||
| Claims priority of provisional application 60/281648, filed on Apr. 04, 2001. | ||
| Claims priority of provisional application 60/509045, filed on Mar. 22, 2001. | ||
| Claims priority of provisional application 60/268558, filed on Feb. 13, 2001. | ||
| Claims priority of provisional application 60/211078, filed on Jun. 13, 2000. | ||
| Claims priority of provisional application 60/157404, filed on Oct. 01, 1999. | ||
| Prior Publication US 2003/0060408 A1, Mar. 27, 2003 | ||
| Int. Cl. C07K 7/00 (2006.01); A61K 38/00 (2006.01) | ||
| U.S. Cl. 514—2 [530/300] | 27 Claims |
| 1. A method of treating an angiogenic disease or condition in an animal comprising administering to the animal an amount of
a metal-binding peptide which does not have a metal ion bound to it or of a physiologically-acceptable salt of the peptide,
the amount of the peptide or salt which is administered to the animal being effective to inhibit angiogenesis, the sequence
of the peptide being:
P1-P2,
wherein:
P1 is:
Xaa1 Xaa2 His or
Xaa1 Xaa2 His Xaa3;
the P1 portion of the peptide being linear;
Xaa1 is the N-terminal amino acid of the peptide, the only substituents on the α-amino group of Xaa1 are hydrogen, and Xaa1 is glycine, alanine, valine, leucine, isoleucine, serine, threonine, aspartic acid, asparagine, glutamic acid, glutamine,
lysine, hydroxylysine, histidine, arginine, ornithine, phenylalanine, tyrosine, tryptophan, cysteine, methionine, or α-hydroxymethylserine;
Xaa2 is alanine, β-alanine, valine, leucine, isoleucine, serine, threonine, aspartic acid, asparagine, glutamic acid, glutamine,
lysine, hydroxylysine, histidine, arginine, ornithine, phenylalanine, tyrosine, tryptophan, cysteine, methionine, or α-hydroxymethylserine;
Xaa3 is glycine, alanine, valine, lysine, arginine, omithine, aspartic acid, glutamic acid, asparagine, glutamine or tryptophan;
and
P2 is an amino acid sequence which comprises the sequence of a Cu(I) binding site, and P2 contains no more than 10 amino acids.
|